Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Resolutions of Delta County Medical Society.

Daniel's Texas medical journal·2023
Same author

The 'difficult-to-treat depression' and the 'response paradigm' models: Implications and relevance to patient management.

The Australian and New Zealand journal of psychiatry·2021
Same author

The identification, assessment and management of difficult-to-treat depression: An international consensus statement.

Journal of affective disorders·2020
Same author

Treatment modalities and outcomes of pleomorphic hyalinizing angiectatic tumor: a systematic review of the literature.

Musculoskeletal surgery·2018
Same author

Increased hippocampal tail volume predicts depression status and remission to anti-depressant medications in major depression.

Molecular psychiatry·2017
Same author

Point : the top 10 reasons for psychopharmacology supervision.

Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry·2014

Related Experiment Video

Updated: Jul 3, 2026

Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
12:21

Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram

Published on: November 27, 2016

SLC6A4 variation and citalopram response.

D A Mrazek1, A J Rush, J M Biernacka

  • 1Mayo Clinic, Department of Psychiatry and Psychology, Rochester, Minnesota, USA. mrazek.david@mayo.edu

American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics
|July 12, 2008
PubMed
Summary

Genetic variations in the SLC6A4 gene influence citalopram treatment outcomes for depression. Specific SLC6A4 polymorphisms are linked to remission in white non-Hispanic adults, suggesting a role in antidepressant response.

Related Experiment Videos

Last Updated: Jul 3, 2026

Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
12:21

Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram

Published on: November 27, 2016

Area of Science:

  • Pharmacogenetics
  • Neuroscience
  • Genetics

Background:

  • The serotonin transporter gene (SLC6A4) plays a crucial role in regulating serotonin levels, impacting mood and response to antidepressants.
  • Genetic variations within SLC6A4 have been investigated for their influence on antidepressant efficacy, particularly with selective serotonin reuptake inhibitors (SSRIs) like citalopram.
  • Previous studies have identified several polymorphisms in SLC6A4, but their combined and individual effects on treatment outcomes require further elucidation.

Purpose of the Study:

  • To investigate the association between genetic variations in the SLC6A4 gene and treatment response to citalopram in a large depression cohort.
  • To examine specific polymorphisms (intron 2 VNTR, 5HTTLPR, rs25531) and novel SNPs within SLC6A4 for their impact on depressive symptom remission.
  • To explore potential ethnic differences in the relationship between SLC6A4 variants and citalopram efficacy.

Main Methods:

  • Genotyping of 1914 subjects from the Sequenced Treatment to Relieve Depression (STAR*D) study for key SLC6A4 polymorphisms (intron 2 VNTR, 5HTTLPR, rs25531).
  • Resequencing of the SLC6A4 gene to identify novel single nucleotide polymorphisms (SNPs) for exploratory analysis.
  • Statistical evaluation of associations between SLC6A4 variants, haplotypes, and remission from depressive symptoms following citalopram treatment, stratified by ethnicity.

Main Results:

  • In white non-Hispanic subjects, variations in the intron 2 VNTR and the 5HTTLPR promoter polymorphism were significantly associated with remission after citalopram treatment.
  • A specific haplotype composed of the three candidate loci demonstrated a significant association with remission in this population.
  • No significant associations were found between the studied SLC6A4 variations and citalopram treatment remission in white Hispanic or black subjects.

Conclusions:

  • Multiple genetic variations within the SLC6A4 gene are associated with achieving remission in white non-Hispanic adults with depression treated with citalopram.
  • These findings highlight the potential role of SLC6A4 pharmacogenetics in predicting antidepressant response in specific ethnic groups.
  • Further research is needed to determine the precise functional mechanisms by which these SLC6A4 variants influence citalopram's effectiveness.